Innate Pharma S.A.
117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 179
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Herve Brailly Ph.D. | Co-Founder, Interim CEO & Chairman of Executive Board | 無 | 無 | 1961 |
| Mr. Yannis Morel Ph.D. | Executive VP, COO & Member of Executive Board | 387.7k | 無 | 1973 |
| Dr. François Romagné Ph.D. | Founder | 無 | 無 | 1964 |
| Mr. Eric Vivier D.V.M., M.B.A., Ph.D. | Founder, Senior VP & Chief Scientific Officer | 無 | 無 | 1964 |
| Dr. Marc Bonneville Ph.D. | Founder | 無 | 無 | 1960 |
| Mr. Jean Jacques Fournié Ph.D. | Founder | 無 | 無 | 無 |
| Mr. Alessandro Moretta M.D., Ph.D. | Founder | 無 | 無 | 無 |
| Mr. Frederic Lombard M.B.A. | Senior VP & CFO | 無 | 無 | 1975 |
| Dr. Sonia Quaratino M.D., Ph.D. | Executive VP, Chief Medical Officer & Member of Executive Board | 無 | 無 | 1967 |
| Mr. Arvind Sood | Executive VP, President of US Operations & Member of Executive Board | 無 | 無 | 無 |
描述
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
公司管治
截至 2024年5月1日 止，Innate Pharma S.A. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：8；董事會：9；股東權利：4；現金賠償：10。
